|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CREB3L3 |
Gene summary for CREB3L3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CREB3L3 | Gene ID | 84699 |
| Gene name | cAMP responsive element binding protein 3 like 3 | |
| Gene Alias | CREB-H | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0002526 | UniProtAcc | Q68CJ9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84699 | CREB3L3 | HCC1_Meng | Human | Liver | HCC | 1.56e-15 | -3.25e-02 | 0.0246 |
| 84699 | CREB3L3 | HCC1 | Human | Liver | HCC | 1.68e-02 | 2.17e+00 | 0.5336 |
| 84699 | CREB3L3 | HCC2 | Human | Liver | HCC | 3.20e-11 | 3.62e+00 | 0.5341 |
| 84699 | CREB3L3 | Pt13.b | Human | Liver | HCC | 4.05e-02 | 1.07e-01 | 0.0251 |
| 84699 | CREB3L3 | S027 | Human | Liver | HCC | 1.60e-19 | 2.16e+00 | 0.2446 |
| 84699 | CREB3L3 | S028 | Human | Liver | HCC | 8.84e-40 | 1.83e+00 | 0.2503 |
| 84699 | CREB3L3 | S029 | Human | Liver | HCC | 1.62e-40 | 2.09e+00 | 0.2581 |
| 84699 | CREB3L3 | Pat01-B | Human | Stomach | GC | 1.23e-51 | 1.03e+00 | 0.5754 |
| 84699 | CREB3L3 | Pat02-B | Human | Stomach | GC | 3.29e-02 | 1.57e-01 | 0.0368 |
| 84699 | CREB3L3 | Pat03-B | Human | Stomach | GC | 1.66e-30 | 7.46e-01 | 0.3693 |
| 84699 | CREB3L3 | Pat17-B | Human | Stomach | GC | 2.05e-17 | 4.85e-01 | 0.3109 |
| 84699 | CREB3L3 | SIM_1 | Human | Stomach | SIM | 1.95e-05 | 2.54e-01 | 0.3573 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003497612 | Liver | HCC | response to endoplasmic reticulum stress | 189/7958 | 256/18723 | 1.43e-24 | 4.06e-22 | 189 |
| GO:003596612 | Liver | HCC | response to topologically incorrect protein | 123/7958 | 159/18723 | 2.60e-19 | 3.44e-17 | 123 |
| GO:000698612 | Liver | HCC | response to unfolded protein | 103/7958 | 137/18723 | 6.50e-15 | 4.48e-13 | 103 |
| GO:003596712 | Liver | HCC | cellular response to topologically incorrect protein | 89/7958 | 116/18723 | 5.61e-14 | 3.39e-12 | 89 |
| GO:003462012 | Liver | HCC | cellular response to unfolded protein | 71/7958 | 96/18723 | 3.70e-10 | 1.22e-08 | 71 |
| GO:003096811 | Liver | HCC | endoplasmic reticulum unfolded protein response | 56/7958 | 74/18723 | 6.47e-09 | 1.67e-07 | 56 |
| GO:004362022 | Liver | HCC | regulation of DNA-templated transcription in response to stress | 43/7958 | 53/18723 | 9.27e-09 | 2.33e-07 | 43 |
| GO:004361822 | Liver | HCC | regulation of transcription from RNA polymerase II promoter in response to stress | 37/7958 | 47/18723 | 4.37e-07 | 7.23e-06 | 37 |
| GO:003600312 | Liver | HCC | positive regulation of transcription from RNA polymerase II promoter in response to stress | 19/7958 | 24/18723 | 2.80e-04 | 2.02e-03 | 19 |
| GO:00025262 | Liver | HCC | acute inflammatory response | 62/7958 | 112/18723 | 4.06e-03 | 1.77e-02 | 62 |
| GO:00069866 | Stomach | GC | response to unfolded protein | 27/1159 | 137/18723 | 7.03e-08 | 4.62e-06 | 27 |
| GO:00359666 | Stomach | GC | response to topologically incorrect protein | 29/1159 | 159/18723 | 1.37e-07 | 8.14e-06 | 29 |
| GO:00346206 | Stomach | GC | cellular response to unfolded protein | 19/1159 | 96/18723 | 5.58e-06 | 2.20e-04 | 19 |
| GO:00359676 | Stomach | GC | cellular response to topologically incorrect protein | 20/1159 | 116/18723 | 2.74e-05 | 7.80e-04 | 20 |
| GO:00436206 | Stomach | GC | regulation of DNA-templated transcription in response to stress | 12/1159 | 53/18723 | 7.47e-05 | 1.63e-03 | 12 |
| GO:00436186 | Stomach | GC | regulation of transcription from RNA polymerase II promoter in response to stress | 11/1159 | 47/18723 | 1.08e-04 | 2.09e-03 | 11 |
| GO:0030968 | Stomach | GC | endoplasmic reticulum unfolded protein response | 12/1159 | 74/18723 | 1.85e-03 | 1.92e-02 | 12 |
| GO:00349766 | Stomach | GC | response to endoplasmic reticulum stress | 28/1159 | 256/18723 | 2.48e-03 | 2.34e-02 | 28 |
| GO:00359665 | Stomach | SIM | response to topologically incorrect protein | 26/708 | 159/18723 | 2.83e-10 | 6.29e-08 | 26 |
| GO:00069865 | Stomach | SIM | response to unfolded protein | 24/708 | 137/18723 | 3.20e-10 | 6.29e-08 | 24 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501622 | Liver | HCC | Huntington disease | 219/4020 | 306/8465 | 3.06e-18 | 3.42e-16 | 1.90e-16 | 219 |
| hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
| hsa0471422 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
| hsa0493121 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
| hsa0516622 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
| hsa0421121 | Liver | HCC | Longevity regulating pathway | 61/4020 | 89/8465 | 4.46e-05 | 2.37e-04 | 1.32e-04 | 61 |
| hsa0415241 | Liver | HCC | AMPK signaling pathway | 77/4020 | 121/8465 | 2.32e-04 | 1.11e-03 | 6.18e-04 | 77 |
| hsa046684 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
| hsa051652 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
| hsa0516322 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
| hsa052032 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
| hsa049624 | Liver | HCC | Vasopressin-regulated water reabsorption | 30/4020 | 44/8465 | 4.41e-03 | 1.32e-02 | 7.34e-03 | 30 |
| hsa0492241 | Liver | HCC | Glucagon signaling pathway | 64/4020 | 107/8465 | 6.70e-03 | 1.87e-02 | 1.04e-02 | 64 |
| hsa049262 | Liver | HCC | Relaxin signaling pathway | 75/4020 | 129/8465 | 9.33e-03 | 2.46e-02 | 1.37e-02 | 75 |
| hsa051612 | Liver | HCC | Hepatitis B | 91/4020 | 162/8465 | 1.56e-02 | 3.76e-02 | 2.09e-02 | 91 |
| hsa0501632 | Liver | HCC | Huntington disease | 219/4020 | 306/8465 | 3.06e-18 | 3.42e-16 | 1.90e-16 | 219 |
| hsa0502032 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
| hsa0471432 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
| hsa0493131 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
| hsa0516632 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CREB3L3 | SNV | Missense_Mutation | rs773414002 | c.60N>G | p.Ile20Met | p.I20M | Q68CJ9 | protein_coding | tolerated(0.36) | benign(0.04) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| CREB3L3 | SNV | Missense_Mutation | novel | c.247N>A | p.Glu83Lys | p.E83K | Q68CJ9 | protein_coding | tolerated(0.06) | benign(0.022) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CREB3L3 | SNV | Missense_Mutation | novel | c.735N>C | p.Lys245Asn | p.K245N | Q68CJ9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CREB3L3 | SNV | Missense_Mutation | novel | c.382N>A | p.Pro128Thr | p.P128T | Q68CJ9 | protein_coding | tolerated(0.05) | benign(0.058) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| CREB3L3 | SNV | Missense_Mutation | c.230N>T | p.Ser77Phe | p.S77F | Q68CJ9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EW-A1PB-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CREB3L3 | insertion | Frame_Shift_Ins | novel | c.1016_1017insATTAATGCAGAAATGGGACCTAGGAACCAGG | p.Ser340LeufsTer45 | p.S340Lfs*45 | Q68CJ9 | protein_coding | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CREB3L3 | SNV | Missense_Mutation | novel | c.323C>T | p.Thr108Ile | p.T108I | Q68CJ9 | protein_coding | tolerated(0.1) | benign(0.024) | TCGA-C5-A3HF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| CREB3L3 | SNV | Missense_Mutation | novel | c.286N>T | p.Asp96Tyr | p.D96Y | Q68CJ9 | protein_coding | deleterious(0.05) | probably_damaging(0.994) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
| CREB3L3 | SNV | Missense_Mutation | novel | c.287N>C | p.Asp96Ala | p.D96A | Q68CJ9 | protein_coding | deleterious(0.02) | probably_damaging(0.952) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
| CREB3L3 | SNV | Missense_Mutation | novel | c.750A>C | p.Lys250Asn | p.K250N | Q68CJ9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |